Fibrinogen-associated binding partners

Fibrinogen-associated binding partners refer to a diverse group of proteins and receptors that interact with fibrinogen (Factor I) or its activated form, fibrin, to regulate critical physiological processes such as hemostasis, thrombosis, and wound healing [1, 2]. Fibrinogen is a large, "sticky" glycoprotein that serves as a central scaffold in the coagulation cascade, providing multiple binding sites for various partners including the platelet integrin alpha-IIb/beta-3 (GPIIb/IIIa), thrombin, factor XIII, and components of the fibrinolytic system like plasminogen and tissue plasminogen activator (tPA) [2, 3]. These interactions are essential for the formation and stabilization of blood clots, as well as their eventual degradation. In addition to its role in clotting, fibrinogen and its associated partners, such as fibrinogen-like protein 1 (FGL1), are increasingly recognized for their roles in inflammation and immune evasion in cancer, where FGL1 acts as a ligand for the inhibitory receptor LAG-3 [4]. Consequently, many of these binding partners are major therapeutic targets; for instance, GPIIb/IIIa inhibitors are used to prevent platelet aggregation in acute coronary syndromes, while thrombolytic agents target the fibrin-plasminogen complex to dissolve pathological clots [3, 5].

Other names

Fibrinogen-binding proteinsFibrinogen receptorsFibrin-binding proteinsFibrinogen interactorsFibrinogen-associated proteins

Drugs targeting fibrinogen-associated binding partners primarily work by inhibiting platelet aggregation (e.g., GPIIb/IIIa antagonists), promoting the dissolution of fibrin clots (e.g., thrombolytics), or modulating immune responses (e.g., LAG-3 inhibitors that block FGL1 binding).